Further Letter of Intent


 

TIDMHML 
 
RNS Number : 1824H 
Henderson Morley PLC 
16 February 2010 
 

                                                              16 February 2010 
 
 
                              HENDERSON MORLEY PLC 
 
                                   (AIM: HML) 
 
                            FURTHER LETTER OF INTENT 
 
The Board of Henderson Morley plc ("Henderson Morley"), the AIM quoted 
biotechnology company, is pleased to announce that it has received a Letter of 
Intent ("LOI"), from a specialist therapeutic drug development company in 
respect of the intellectual property rights (IPR) of Henderson Morley's ICVT 
portfolio, specifically the Recurrent Respiratory Papilloma ("RRP") indication. 
This LOI is additional to the LOI received by the Company in 2009 (see 
announcement 8 October 2009). 
 
 The proposed sale of this IPR is still subject to further negotiation and 
it is anticipated that a decision acceptable to each party will be completed 
within approximately 45 days. 
 
 The specialist therapeutic drug development 
company was established by a number of former Merck Generics Senior Executives 
including Hank Klakurka, former CEO, Steve Self, former Global R&D Director and 
Martin Marino, former Chief Legal Counsel. This company's model takes high 
potential drug candidates through clinical trials, regulatory and into 
production and sales. It currently has four development projects in its 
pipeline, one of which is a respiratory project and the other three are 
anti-infectives. 
 
RRP is a rare and life threatening condition, that is characterised by the 
growth of warts within the respiratory tract of sufferers. This may cause 
blockage of the airway, which currently necessitates surgery, often required on 
numerous occasions in affected individuals. As announced on 25 November 2009 the 
Company submitted an orphan designation application to both the FDA and the 
EMEA, which if successful, will give the RRP application of ICVT, 'orphan 
status'. Orphan status allows certain regulatory and commercial advantages, such 
as market exclusivity, reduced application fees and availability of grants. 
Discussions to purchase the IPR regarding ICVT include, but are not limited to, 
the orphan indication. 
 
 Simultaneously, Henderson Morley continues to negotiate with other parties 
in respect of the sale of ICVT applications. This includes the specialist 
pharmaceutical company based outside the EU that sent Henderson Morley an LOI in 
October 2009 indicating its interest in the human applications of ICVT. 
Henderson Morley specifically excluded from these negotiations, RRP, ophthalmic, 
and veterinarian applications of ICVT. 
 
 Commenting on this additional 
Letter of Intent, Executive Chairman Andrew Knight said: "We are delighted at 
the interest the sale of ICVT has generated and we are continuing negotiations 
with a number of parties and hope to conclude a deal as soon as 
possible. 
 
 "The funds raised by the sale of ICVT will be used to bring the 
Company's stated strategy of becoming a 'Pure Play' vaccine Company to fruition" 
 
 
 
                                      -END- 
 
 
 
Enquires 
 
HENDERSON MORLEY PLC 
0121 442 4600 
Andrew Knight, Chairman 
 
BISHOPSGATECOMMUNICATIONS LTD                                        0207 562 
3350 
Maxine Barnes 
Gemma O'Hara 
 
BREWIN DOLPHIN INVESTMENT BANKING                                   0113 241 
0126 
Neil Baldwin 
 
RIVINGTON STREET CORPORATE FINANCE                                 0207 562 3380 
Dru Edmonstone 
 
Further information on Henderson Morley plc can be accessed through the 
Company's website at www.henderson-morley.com 
 
 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 STRLLFVDFAIELII

Henderson Mrly. (LSE:HML)
過去株価チャート
から 5 2024 まで 6 2024